UK markets closed

Allergy Therapeutics plc (AGY.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
26.50+2.75 (+11.58%)
At close: 05:37PM GMT
Full screen
Previous close23.75
Open25.80
Bid26.00 x 0
Ask27.00 x 0
Day's range25.80 - 26.98
52-week range17.75 - 40.50
Volume920,215
Avg. volume248,148
Market cap170.553M
Beta (5Y monthly)1.48
PE ratio (TTM)66.25
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut

    Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022Topline data from first-in-human trial expected in H1 2023Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of action of the vaccine candidate 26 January 2022 Allergy Therapeutics

  • Globe Newswire

    Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL

    Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL Primary endpoint Combined Symptom Medication Score (CSMS) achieved with clinically relevant improvement across both active treatment groups compared to placebo Statistically significant reduction in CSMS seen in both active treatment groups of 29.1% and 36.8% compared to placebo Analysis

  • Globe Newswire

    Preliminary Results for the Year ended 30 June 2021

    Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the Year ended 30 June 2021 Record pre-R&D operating profit ahead of market expectations reflecting continued sales growth Successful ex-vivo VLP Peanut biomarker study showing 24-fold reduction in allergenicity and beneficial efficacy profile paving the way for first-in-human trial in 2022Strong cash balance of £40.3m providing sufficient funds with a small amount of debt under current assumptions to